<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35404" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Milk Thistle</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Achufusi</surname>
            <given-names>Ted George O.</given-names>
          </name>
          <aff>SUNY University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pellegrini</surname>
            <given-names>Mark V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Raj K.</given-names>
          </name>
          <aff>Novant</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ted George Achufusi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Pellegrini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raj Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35404.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Herbal products have gained considerable popularity among individuals grappling with chronic diseases. Among the herbs available, milk thistle stands out as a centuries-old remedy&#x000a0;used by herbalists and clinicians for diverse liver ailments such as fatty liver disease, hepatitis, and cirrhosis. Milk thistle's efficacy in shielding the liver from environmental toxins has contributed to its widespread adoption, with millions incorporating milk thistle into their routines to bolster healthy liver function.</p>
        <p>This course discusses the research surrounding silymarin, an amalgamation of flavonolignans derived from milk thistle, focusing on silybin as its most active component. The discussion will center on elucidating the mechanism of action, outlining the adverse event profile, detailing monitoring procedures, and exploring relevant interactions associated with milk thistle. The insights shared&#x000a0;are invaluable for interprofessional team members involved in the care of patients where milk thistle may offer clinical benefits.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various clinical applications of milk thistle, including its use as a complementary therapy for liver conditions such as hepatitis and cirrhosis.</p></list-item><list-item><p>Apply evidence-based guidelines for using milk thistle, ensuring its integration into patient care is based on current research and recommendations.</p></list-item><list-item><p>Assess the effectiveness of milk thistle in individual patients by monitoring liver function tests and other relevant clinical parameters.</p></list-item><list-item><p>Develop&#x000a0;effective communication with patients about milk thistle's potential benefits and limitations, addressing their questions and concerns.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35404&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35404">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35404.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Herbal products have become increasingly popular, especially among individuals&#x000a0;with chronic diseases. Herbalists and physicians alike used the milk thistle (<italic toggle="yes">Silybum marianum</italic>), an annual or biennial herb from the Mediterranean region, for hundreds of years to treat a wide range of liver pathology, including fatty liver disease, hepatitis, and cirrhosis, and to protect the liver from environmental toxins.<xref ref-type="bibr" rid="article-35404.r1">[1]</xref> Today, millions of people consume milk thistle to support healthy liver function. The ripe seeds are primarily the medicinal part of the plant.<xref ref-type="bibr" rid="article-35404.r2">[2]</xref></p>
        <p>Researchers have focused their efforts on studying silymarin, a mixture of flavonolignans extracted from milk thistle, and the most active ingredient of this extract, silybin.<xref ref-type="bibr" rid="article-35404.r3">[3]</xref> Silymarin and silybin have become some of the most prescribed natural compounds,&#x000a0;and the&#x000a0;2 names are often interchangeable. However, each has a different clinical purpose, but there are no definitive results in terms of clinical efficacy. Currently, herbal products such as milk thistle in the United States are not considered drugs and&#x000a0;do not have the same level of regulation as drugs from the US&#x000a0;Food and Drug Administration (FDA).<xref ref-type="bibr" rid="article-35404.r4">[4]</xref> Like most herbal products, the FDA does not approve or recommend milk thistle as a treatment for any medical condition.</p>
        <p>Recent studies have focused on the role of milk thistle in treating nonalcoholic fatty liver disease, a common hepatic manifestation of metabolic syndrome. The prevalence of NAFLD in Western countries is approximately 20% to 30%.<xref ref-type="bibr" rid="article-35404.r5">[5]</xref><xref ref-type="bibr" rid="article-35404.r6">[6]</xref> Currently, there is no consensus approach when it comes to the treatment of NAFLD. Most clinicians approach the disease by emphasizing lifestyle modification, including diet, weight loss, and limiting alcohol intake. However, study results suggest milk thistle can benefit patients with NAFLD. Data indicate that silymarin treatment correlated with reduced insulin resistance and decreased fasting insulin levels significantly. Patients treated with 600 mg/d of silymarin for 12 months demonstrated lower fasting insulin levels.<xref ref-type="bibr" rid="article-35404.r7">[7]</xref> A separate clinical trial evaluated silymarin's effectiveness compared to metformin and pioglitazone in NAFLD patients. Research showed that patients treated with silymarin had significantly lower transaminase levels than those treated with metformin or pioglitazone.<xref ref-type="bibr" rid="article-35404.r8">[8]</xref>&#x000a0;</p>
        <p>In a sample of 25 patients treated for&#x000a0;4 months with 200 mg of silymarin&#x000a0;3 times a day before meals, there was a significant reduction in blood glucose levels (from 156 &#x000b1; 46 mg/dL to 133 &#x000b1; 39 mg/dL) compared to an increase in the placebo-treated group. In the same period, their HbA1c levels also dropped by an average of 1 point. The same group of patients also demonstrated significantly reduced total cholesterol, triglycerides, and LDL levels.<xref ref-type="bibr" rid="article-35404.r9">[9]</xref><xref ref-type="bibr" rid="article-35404.r10">[10]</xref>&#x000a0;Another study aimed to evaluate the efficacy of combined treatment, which includes vitamin E, silybin, and phospholipids, and demonstrated that this complex improves liver damage, especially plasma markers of liver fibrosis and insulin resistance.<xref ref-type="bibr" rid="article-35404.r11">[11]</xref>&#x000a0;In Europe, intravenous preparations of purified silibinin are approved as an antidote to&#x000a0;Amanita phalloides, a mushroom toxin that causes severe liver damage.<xref ref-type="bibr" rid="article-35404.r12">[12]</xref></p>
        <p>Early lab studies suggest that silymarin and other active molecules in milk thistle may exhibit anti-cancer effects, including interfering with cancer cell division and reproduction, shortening cancer cell lifespan, and reducing the blood supply to tumors. Other research suggests milk thistle acts synergistically with chemotherapy. More research is necessary to determine whether milk thistle can exhibit this activity in vivo.<xref ref-type="bibr" rid="article-35404.r13">[13]</xref><xref ref-type="bibr" rid="article-35404.r14">[14]</xref><xref ref-type="bibr" rid="article-35404.r15">[15]</xref><xref ref-type="bibr" rid="article-35404.r16">[16]</xref></p>
      </sec>
      <sec id="article-35404.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Milk thistle exhibits its hepatoprotective properties by&#x000a0;3 major mechanisms: an antioxidant, an anti-inflammatory, and an antifibrotic substance.<xref ref-type="bibr" rid="article-35404.r17">[17]</xref> The anti-inflammatory properties of milk thistle are attributable to its ability to regulate cytokines responsible for inducing inflammation. Milk thistle has been shown to down-regulate and inhibit the expression of COX-2, a key mediator of inflammatory pathways.<xref ref-type="bibr" rid="article-35404.r17">[17]</xref><xref ref-type="bibr" rid="article-35404.r18">[18]</xref> Silymarin also inhibits the transduction cascade controlled by NF-&#x003ba;B. This protein complex induces the expression of pro-inflammatory genes responsible for encoding cytokines directly involved in the inflammatory process. NF-&#x003ba;B also regulates the survival of inflammatory T-cells. Studies done on mice showed silybin reduced liver and plasma content of pro-inflammatory cytokines while increasing IL-10, a cytokine whose function is to decrease and regulate the inflammatory response.<xref ref-type="bibr" rid="article-35404.r19">[19]</xref><xref ref-type="bibr" rid="article-35404.r20">[20]</xref></p>
        <p>Milk thistle has also shown antioxidant properties in hepatocytes and can inhibit free radicals derived from the metabolism of toxic substances such as ethanol, acetaminophen, and carbon tetrachloride. This herb stimulates protein synthesis by protecting cell membranes from free radical-induced damage and directly inhibiting radical formation.&#x000a0;Milk thistle can also act as a free radical scavenger and increase the intracellular content of scavengers.<xref ref-type="bibr" rid="article-35404.r21">[21]</xref>&#x000a0;Studies have shown that silymarin increases superoxide dismutase activity and serum glutathione and glutathione peroxidase levels.<xref ref-type="bibr" rid="article-35404.r22">[22]</xref><xref ref-type="bibr" rid="article-35404.r23">[23]</xref>&#x000a0;Silybin can also act as an iron chelator, further strengthening its antioxidant properties.<xref ref-type="bibr" rid="article-35404.r24">[24]</xref></p>
        <p>In addition to its anti-inflammatory and antioxidant properties, silybin also shows promise as an antifibrotic agent, which is attributable to its ability to decrease platelet-derived growth factor (PDGF)-induced DNA synthesis in cells, which inhibits the transformation of stellate hepatocytes into myofibroblasts. By reducing myofibroblasts, silybin indirectly prevents the deposition of collagen fibers that lead to the progression of liver injury.<xref ref-type="bibr" rid="article-35404.r17">[17]</xref> Finally, silybin has demonstrated an association with a significant reduction of TGF-&#x003b2;, a key regulator in the pathogenesis of liver fibrosis.<xref ref-type="bibr" rid="article-35404.r25">[25]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Small studies have demonstrated&#x000a0;that flavonolignans were rapidly absorbed and eliminated after oral administration of standardized milk thistle extract.<xref ref-type="bibr" rid="article-35404.r26">[26]</xref><xref ref-type="bibr" rid="article-35404.r27">[27]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Pharmacokinetic parameters appear to indicate a dose-dependent volume of distribution&#x000a0;of some component phytochemicals in single-dose escalation assessments, with some of these compounds only detectable at the highest dose.<xref ref-type="bibr" rid="article-35404.r26">[26]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Research indicates that silymarin extracts undergo extensive metabolism; most of&#x000a0;milk thistle's phytochemicals are subject to phase II hepatic metabolic processes (eg, glucuronidation, sulfation).<xref ref-type="bibr" rid="article-35404.r26">[26]</xref>&#x000a0;Other research also concluded that since&#x000a0;milk thistle flavonolignans are extensively modified following oral dosing and are recovered in the urine as sulpho- and glucuronyl conjugates,&#x000a0;this analysis demonstrates&#x000a0;a strong&#x000a0;link to&#x000a0;hepatic phase II metabolism.<xref ref-type="bibr" rid="article-35404.r27">[27]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;The parent compounds found in milk thistle and their metabolites may enter the internal circulation and are excreted in the bile or urine. Milk thistle flavonolignans&#x000a0;metabolites&#x000a0;are recovered in urine.<xref ref-type="bibr" rid="article-35404.r27">[27]</xref></p>
      </sec>
      <sec id="article-35404.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Adult Dosing</bold>
</p>
        <p>Like most herbal supplements, milk thistle is orally administered and is available in capsules, tablets, or as a liquid extract&#x000a0;containing&#x000a0;ethanol-extracted silymarin in doses of 250 to 750 mg. The daily dosage varies, but the typical dose&#x000a0;frequency is 2 to 3 times daily.&#x000a0;Research shows that&#x000a0;silymarin is generally safe in humans at standard therapeutic doses and is even well tolerated at higher doses of 700&#x000a0;mg&#x000a0;3 times a day for 24&#x000a0;weeks.<xref ref-type="bibr" rid="article-35404.r28">[28]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Despite milk thistle's&#x000a0;use in patients with and without liver disease,&#x000a0;it has not been implicated in altering liver function tests or causing&#x000a0;clinically&#x000a0;relevant acute&#x000a0;hepatic injury.<xref ref-type="bibr" rid="article-35404.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Renal impairment:</bold>&#x000a0;There is&#x000a0;little evidence regarding dosing milk thistle in patients with renal impairment, and in fact, some research suggests milk thistle may be renoprotective.<xref ref-type="bibr" rid="article-35404.r29">[29]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Caution&#x000a0;is recommended during pregnancy, as more studies are needed on milk thistle and pregnancy, especially in humans.<xref ref-type="bibr" rid="article-35404.r30">[30]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Limited data indicate that the silymarin components of milk thistle are not excreted into breast milk in measurable amounts.<xref ref-type="bibr" rid="article-35404.r31">[31]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;No studies exist examining whether pediatric use of milk thistle is safe.</p>
        <p><bold>Older&#x000a0;patients:</bold>&#x000a0;No data implicates milk thistle as causing problems in older patients. Clinicians should exercise caution and monitor older patients who take milk thistle.</p>
      </sec>
      <sec id="article-35404.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>According to pharmacological studies, silymarin is recognized as a safe herbal product since taking it at therapeutic doses is not toxic.<xref ref-type="bibr" rid="article-35404.r17">[17]</xref>&#x000a0;Although rare, some of the adverse effects of milk thistle include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastroenteritis</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Bloating</p>
          </list-item>
          <list-item>
            <p>Dermatological symptoms (eg, hives, rash, pruritus)</p>
          </list-item>
        </list>
        <p>Oral silymarin generally has few, if any, adverse effects and is well-tolerated even at higher doses.&#x000a0;Milk thistle may prompt an allergic reaction in individuals sensitive to the <italic toggle="yes">Asteraceae</italic>/<italic toggle="yes">Compositae</italic> plant family (eg,&#x000a0;ragweed, chrysanthemums, marigolds).</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Milk thistle does not have any documented significant drug-drug interactions. However, since it does exert some effect on the CYP450 enzyme system, it might affect certain drugs, including diazepam and warfarin. However, this effect is not potent or even moderate at recommended doses.<xref ref-type="bibr" rid="article-35404.r32">[32]</xref>&#x000a0;Some researchers have noted an association between milk thistle and bleeding in patients on blood thinners.<xref ref-type="bibr" rid="article-35404.r33">[33]</xref>&#x000a0;Caution is advised with narrow therapeutic window medications.<xref ref-type="bibr" rid="article-35404.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Since milk thistle appears to be able to lower blood sugar, it may have an additive effect with other medications for type 2 diabetes.<xref ref-type="bibr" rid="article-35404.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Milk thistle may affect the hepatic metabolism of raloxifene by inhibiting raloxifene glucuronidation.<xref ref-type="bibr" rid="article-35404.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35404.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are currently no documented contraindications to using milk thistle. However, there is little information about milk thistle's interactions with cancer drugs, radiation therapy, or other medications.<xref ref-type="bibr" rid="article-35404.r2">[2]</xref></p>
      </sec>
      <sec id="article-35404.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As&#x000a0;with most herbal products, there is no&#x000a0;definitive way to monitor blood levels of milk thistle or its compounds, and little data is available on the therapeutic index of the supplement. However, silymarin has been shown to decrease the activity of cytochrome P-450 enzymes and UDP-glucuronosyltransferase (UGT) enzymes, prompting healthcare providers to caution patients against co-administration of milk thistle and specific pharmaceutical agents.</p>
      </sec>
      <sec id="article-35404.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Asymptomatic liver toxicity in clinical trials performed on cancer patients has been reported; researchers observed an increase in ALT and bilirubin levels. However, this observation was at extremely high doses of silybin (between 10 to 20 g/d).<xref ref-type="bibr" rid="article-35404.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-35404.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Research&#x000a0;has indicated that milk thistle has the potential to reduce biochemical changes seen in patients with NAFLD, and multiple pharmacological studies have demonstrated why many consider the plant to be a hepatoprotective substance. Based on the data available, many believe that milk thistle represents a&#x000a0;viable alternative for patients with acute and chronic liver disease, especially those in whom standard therapy has failed. However, more evidence is needed to establish milk thistle's short-term and long-term effects. Other studies have shown potential therapeutic effects such as anticancer, anti-diabetic, anti-Alzheimer, and anti-Parkinson effects, so interest in researching this supplement&#x000a0;remains high.<xref ref-type="bibr" rid="article-35404.r30">[30]</xref></p>
        <p>Healthcare workers, including physicians, nurse practitioners, nursing staff, and pharmacists, should be aware that currently, there is no firm clinical evidence to recommend silybin or silymarin in the clinical setting.<xref ref-type="bibr" rid="article-35404.r36">[36]</xref>&#x000a0;Providers must function as an interprofessional team to ensure that all care team members know what drugs and supplements the patient might take. Physicians, advanced practice practitioners, nurses, and pharmacists need to inquire about non-prescription agents that the patient may be using, and milk thistle would be included in this query as an over-the-counter substance. The pharmacist&#x000a0;must consider milk thistle and other OTC substances in their medication reconciliation and alert the rest of the team to its presence in the patient's regimen and any potential interactions. Nursing staff should be aware of the pharmacology of milk thistle and document it in the patient's&#x000a0;medical record so all other healthcare team members can be informed. All healthcare team members need to make the patient understand that just because milk thistle is available over the counter&#x000a0;does not mean it is a benign substance. This type of collaboration on the interprofessional team is crucial to managing patient outcomes effectively.</p>
        <p>Using milk thistle is inconsistent with the established standard of care. There have been thousands of papers published on milk thistle to date, and the high publication volume suggests that interest among the research community remains high. Future research should continue to assess the mechanisms for preventing inflammatory sequelae and the cytoprotective&#x000a0;effects of milk thistle, including silymarin and silybin. This research will allow for better recognition of cellular targets of milk thistle, leading to a more potent and selective compound that could prove clinically useful in treating a wide variety of liver pathology.</p>
      </sec>
      <sec id="article-35404.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35404&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35404">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35404/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35404">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35404.s11">
        <title>References</title>
        <ref id="article-35404.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Milk Thistle</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">31644124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nawaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zaib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahzadi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title><italic>Silybum marianum</italic>: An Overview of its Phytochemistry and Pharmacological Activities with Emphasis on Potential Anticancer Properties.</article-title>
            <source>Anticancer Agents Med Chem</source>
            <year>2023</year>
            <volume>23</volume>
            <issue>13</issue>
            <fpage>1519</fpage>
            <page-range>1519-1534</page-range>
            <pub-id pub-id-type="pmid">37055902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bijak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.</article-title>
            <source>Molecules</source>
            <year>2017</year>
            <month>Nov</month>
            <day>10</day>
            <volume>22</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">29125572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dwyer</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Dietary Supplements: Regulatory Challenges and Research Resources.</article-title>
            <source>Nutrients</source>
            <year>2018</year>
            <month>Jan</month>
            <day>04</day>
            <volume>10</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29300341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Global challenges in liver disease.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>521</fpage>
            <page-range>521-6</page-range>
            <pub-id pub-id-type="pmid">16941687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bedogni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miglioli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Masutti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tiribelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchesini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bellentani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.</article-title>
            <source>Hepatology</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-52</page-range>
            <pub-id pub-id-type="pmid">15895401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velussi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cernigoi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>De Monte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dapas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caffau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zilli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients.</article-title>
            <source>J Hepatol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>871</fpage>
            <page-range>871-9</page-range>
            <pub-id pub-id-type="pmid">9126802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hajiaghamohammadi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ziaee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oveisi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Masroor</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.</article-title>
            <source>Hepat Mon</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>e6099</fpage>
            <pub-id pub-id-type="pmid">23087748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazazis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Evangelopoulos</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kollas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vallianou</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>The therapeutic potential of milk thistle in diabetes.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2014</year>
            <season>Summer</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-74</page-range>
            <pub-id pub-id-type="pmid">25396404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huseini</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Larijani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heshmat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fakhrzadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Radjabipour</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Toliat</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.</article-title>
            <source>Phytother Res</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>1036</fpage>
            <page-range>1036-9</page-range>
            <pub-id pub-id-type="pmid">17072885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loguercio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trappoliere</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuccillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Sio</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Di Leva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niosi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Auria</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Vecchio Blanco</surname>
                <given-names>C</given-names>
              </name>
              <collab>Real Sud Group</collab>
            </person-group>
            <article-title>The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.</article-title>
            <source>Dig Dis Sci</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>2387</fpage>
            <page-range>2387-95</page-range>
            <pub-id pub-id-type="pmid">17410454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hruby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Csomos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fuhrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaler</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy of Amanita phalloides poisoning with intravenous silibinin.</article-title>
            <source>Hum Toxicol</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-95</page-range>
            <pub-id pub-id-type="pmid">6862461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahnama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tehrankhah</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Mohajerani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Yeganeh</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Najafi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Babashah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sadeghizadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis.</article-title>
            <source>BMC Complement Med Ther</source>
            <year>2023</year>
            <month>Sep</month>
            <day>26</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>337</fpage>
            <pub-id pub-id-type="pmid">37749575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jo</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Silibinin Inhibits Cell Invasion through the Inhibition of MMPs, <italic>p</italic>-p38, and IL-1&#x003b2; in Human Fibrosarcoma Cells.</article-title>
            <source>Front Biosci (Landmark Ed)</source>
            <year>2023</year>
            <month>Apr</month>
            <day>06</day>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">37114542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iqbal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chattopadhyay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ur Rehman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakasam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bamezai</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.</article-title>
            <source>FEBS J</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>288</volume>
            <issue>2</issue>
            <fpage>471</fpage>
            <page-range>471-485</page-range>
            <pub-id pub-id-type="pmid">32356386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawaguchi-Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frye</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Brinda</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chavin</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>1611</fpage>
            <page-range>1611-6</page-range>
            <pub-id pub-id-type="pmid">25028567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loguercio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Festi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Silybin and the liver: from basic research to clinical practice.</article-title>
            <source>World J Gastroenterol</source>
            <year>2011</year>
            <month>May</month>
            <day>14</day>
            <volume>17</volume>
            <issue>18</issue>
            <fpage>2288</fpage>
            <page-range>2288-301</page-range>
            <pub-id pub-id-type="pmid">21633595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abenavoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellentani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>677</fpage>
            <page-range>677-9</page-range>
            <pub-id pub-id-type="pmid">24134155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000fc;mann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prockl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kiemer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Vollmar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tiegs</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Silibinin protects mice from T cell-dependent liver injury.</article-title>
            <source>J Hepatol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-40</page-range>
            <pub-id pub-id-type="pmid">12927918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beyo&#x0011f;lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Idle</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Metabolomic insights into the mode of action of natural products in the treatment of liver disease.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>180</volume>
            <fpage>114171</fpage>
            <pub-id pub-id-type="pmid">32710968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trouillas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marsal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Svobodov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vost&#x000e1;lov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaz&#x000e1;k</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hrb&#x000e1;c</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sedmera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kren</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lazzaroni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duroux</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Walterov&#x000e1;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study.</article-title>
            <source>J Phys Chem A</source>
            <year>2008</year>
            <month>Feb</month>
            <day>07</day>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>1054</fpage>
            <page-range>1054-63</page-range>
            <pub-id pub-id-type="pmid">18193843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wellington</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Silymarin: a review of its clinical properties in the management of hepatic disorders.</article-title>
            <source>BioDrugs</source>
            <year>2001</year>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>465</fpage>
            <page-range>465-89</page-range>
            <pub-id pub-id-type="pmid">11520257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacciapuoti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scognamiglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Forte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cacciapuoti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Silymarin in non alcoholic fatty liver disease.</article-title>
            <source>World J Hepatol</source>
            <year>2013</year>
            <month>Mar</month>
            <day>27</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>109</fpage>
            <page-range>109-13</page-range>
            <pub-id pub-id-type="pmid">23556042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borsari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabbi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ghelfi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grandi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saladini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Severi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borella</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Silybin, a new iron-chelating agent.</article-title>
            <source>J Inorg Biochem</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>85</volume>
            <issue>2-3</issue>
            <fpage>123</fpage>
            <page-range>123-9</page-range>
            <pub-id pub-id-type="pmid">11410232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabregat</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moreno-C&#x000e0;ceres</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dooley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dewidar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giannelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ten Dijke</surname>
                <given-names>P</given-names>
              </name>
              <collab>IT-LIVER Consortium</collab>
            </person-group>
            <article-title>TGF-&#x003b2; signalling and liver disease.</article-title>
            <source>FEBS J</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>283</volume>
            <issue>12</issue>
            <fpage>2219</fpage>
            <page-range>2219-32</page-range>
            <pub-id pub-id-type="pmid">26807763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Brinda</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chavin</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>1679</fpage>
            <page-range>1679-85</page-range>
            <pub-id pub-id-type="pmid">23835761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brighenti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Absorption and metabolism of milk thistle flavanolignans in humans.</article-title>
            <source>Phytomedicine</source>
            <year>2012</year>
            <month>Dec</month>
            <day>15</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">23072776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raclariu-Manolic&#x00103;</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Socaciu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Detecting and Profiling of Milk Thistle Metabolites in Food Supplements: A Safety-Oriented Approach by Advanced Analytics.</article-title>
            <source>Metabolites</source>
            <year>2023</year>
            <month>Mar</month>
            <day>17</day>
            <volume>13</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36984880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rafieian-Kopaie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasri</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Silymarin and diabetic nephropathy.</article-title>
            <source>J Renal Inj Prev</source>
            <year>2012</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">25340091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soleimani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Delghandi</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Moallem</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review.</article-title>
            <source>Phytother Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>1627</fpage>
            <page-range>1627-1638</page-range>
            <pub-id pub-id-type="pmid">31069872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Milk Thistle</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wanwimolruk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prachayasittikul</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).</article-title>
            <source>EXCLI J</source>
            <year>2014</year>
            <volume>13</volume>
            <fpage>347</fpage>
            <page-range>347-91</page-range>
            <pub-id pub-id-type="pmid">26417265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatfield</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Housewright</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Dietary supplements and bleeding.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2022</year>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>802</fpage>
            <page-range>802-807</page-range>
            <pub-id pub-id-type="pmid">36304597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Necyk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zubach-Cassano</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Natural Health Products and Diabetes: A Practical Review.</article-title>
            <source>Can J Diabetes</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>642</fpage>
            <page-range>642-647</page-range>
            <pub-id pub-id-type="pmid">28826695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gufford</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vergara</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oberlies</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Paine</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>1353</fpage>
            <page-range>1353-9</page-range>
            <pub-id pub-id-type="pmid">26070840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35404.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamayo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).</article-title>
            <source>Integr Cancer Ther</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-57</page-range>
            <pub-id pub-id-type="pmid">17548793</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
